Home Archive Collections Podcast Video Info & Services
Skip Navigation LinksHome > Collections > Multiple Sclerosis Therapies and Research

Multiple Sclerosis Therapies and Research

Created:   1/26/2010
Contains:  44 items

Show
Previous of 3 Next

FROM THE AAN: A New Evidence-Based Guideline on Complementary and Alternative Medicine for MS

Free Access
PDF
+ Favorites
Request Permissions

Will New Data on Gray Matter Dysfunction in MS Upend Theory on Disease Demyelination?

Free Access
PDF
+ Favorites
Request Permissions

PML in Suspected MS Patient Taking Fingolimod Raises FDA Concerns

Free Access
PDF
+ Favorites
Request Permissions

Glaxo Under Fire Over MS Clinical Trial Allegations at R&D Center in China

Free Access
PDF
+ Favorites
Request Permissions

PML Reported in Patients Taking Psoriasis Compounds Sharing Ingredient with Oral MS Drug

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: What Are the Risks That Radiologically Isolated Syndrome Will Convert to MS?

Free Access
PDF
+ Favorites
Request Permissions

With New Oral Ms Drug, New Therapeutic Options

Free Access
PDF
+ Favorites
Request Permissions

Cognitive Impairment May Vary Depending on the Type of MS

Free Access
PDF
+ Favorites
Request Permissions

Imaging Tracks Fibrinogen Activity in MS Brain Inflammation

Free Access
PDF
+ Favorites
Request Permissions

Amyloid Beta Reverses MS-like Disease in Mice. Is It Time to Re-evaluate Amyloid Elsewhere?

Free Access
PDF
+ Favorites
Request Permissions

Serum Levels of Antibodies to a Potassium Channel Found Higher in People with MS

Free Access
PDF
+ Favorites
Request Permissions

Interferon Found Not to Slow MS Disability Progression

Free Access
PDF
+ Favorites
Request Permissions

NEWS FROM THE AAN ANNUAL MEETING: For MS Patients, No Additive Benefit Found in Combining Glatiramer Acetate and Interferon Beta-1A

Free Access
PDF
+ Favorites
Request Permissions

Levels of Risk Identified for MS Patients Taking Natalizumab

Free Access
PDF
+ Favorites
Request Permissions

Fatty Acids Quell Myelin Inflammation in MS model

Free Access
PDF
+ Favorites
Request Permissions

Citing Possible Heart Risks, FDA Recommends Increased Monitoring, Tighter Indications, for MS Patients Prescribed Fingolimod

Free Access
PDF
+ Favorites
Request Permissions

News from the AAN Annual Meeting: Novel Agent Reduces MS. Lesions in Early Trial

Free Access
PDF
+ Favorites
Request Permissions

Will Firategrast, Another Monoclonal Antibody Therapy for MS, Prove a Safe, Effective Alternative?

Free Access
PDF
+ Favorites
Request Permissions

Young Immune Systems Can Rejuvenate Remyelinating Ability

Free Access
PDF
+ Favorites
Request Permissions

A Game-Changer in MS Pathogenesis: New Evidence for Early Cortical Inflammation as Primary Target for Therapy

Free Access
PDF
+ Favorites
Request Permissions
Show
Previous of 3 Next
Collection Alerts

Stay up-to-date! Be notified every time a new item is added. Receive an Email or subscribe to an RSS feed.